SOURCE: Threshold Pharmaceuticals

Threshold Pharmaceuticals

May 09, 2013 07:00 ET

Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, CA--(Marketwired - May 9, 2013) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:

  • BofA Merrill Lynch 2013 Healthcare Conference, May 15, 2013, at 4:00 p.m. ET;

  • 2013 UBS Global Healthcare Conference, May 22, 2013, at 8:30 a.m. ET; and

  • Jeffries 2013 Global Healthcare Conference, June 6, 2013, at 9:30 a.m. ET.

A live webcast of each presentation will be available under Webcasts in the Investors section of A replay of each presentation will be archived on the site for 30 days.

About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (

Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on May 2, 2013 and is available from the SEC's website ( and on our website ( under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

Contact Information

  • Contact
    Laura Hansen, Ph.D.
    Senior Director, Corporate Communications
    Threshold Pharmaceuticals
    Phone: 650-474-8206